HNL Lab Medicine Executive and Leadership Team

Martin Till, the President & Chief Executive Officer at HNL Lab Medicine, directs the overarching strategic vision for the organization. Focusing on the expansion of diagnostic capabilities, the President & Chief Executive Officer manages high-level partnerships with hospitals and industrial clients throughout the Pennsylvania and New Jersey regions. This leadership role involves aligning laboratory infrastructure with evolving healthcare demands to maintain market competitiveness. By optimizing resource allocation, Martin Till ensures the delivery of accurate clinical and anatomic pathology results for a broad patient population. The President & Chief Executive Officer also coordinates with the Board to drive long-term growth and operational excellence. Through constant evaluation of market trends, the President & Chief Executive Officer secures the financial and clinical stability of the laboratory network, ultimately fostering a culture of innovation and reliability across all diagnostic service lines.

David Beckwith, the President & Chief Executive Officer at HNL Lab Medicine, architects the internal governance frameworks necessary for scaling laboratory operations. While the other President & Chief Executive Officer focuses on external growth, Beckwith concentrates on the integration of advanced diagnostic technologies and the streamlining of internal workflows. This role involves overseeing the implementation of quality control protocols across all regional facilities to ensure consistent service delivery. By managing complex organizational transitions, David Beckwith supports the laboratory's mission to provide rapid, reliable testing for long-term care facilities and physician offices. The President & Chief Executive Officer also monitors regulatory compliance and safety standards to mitigate operational risks. Through the continuous refinement of laboratory processes, the President & Chief Executive Officer enhances the efficiency of diagnostic output, directly impacting the speed and accuracy of patient care across the entire service footprint.

David Confalone, the Chief Financial Officer at HNL Lab Medicine, manages the fiscal health and capital investment strategies of the organization. Overseeing the financial planning and analysis departments, the Chief Financial Officer ensures the laboratory maintains the necessary resources to support extensive clinical and anatomic pathology testing. This leadership role involves evaluating the profitability of diagnostic service lines and optimizing cost structures across Pennsylvania and New Jersey operations. By directing budget allocations, David Confalone supports the acquisition of cutting-edge laboratory equipment and the expansion of testing capacity. The Chief Financial Officer also collaborates with the executive team to assess the financial viability of new market opportunities and healthcare partnerships. Through rigorous financial oversight, the Chief Financial Officer secures the long-term sustainability of the company, providing the economic foundation required to deliver high-quality diagnostic services to a diverse range of healthcare providers and industrial clients.

Warren Erdmann, the Chief Operating Officer at HNL Lab Medicine, directs the daily logistics and service delivery functions across the entire laboratory network. Overseeing the complex supply chain and specimen processing workflows, the Chief Operating Officer ensures that hospitals and physician offices receive timely and accurate diagnostic results. This leadership role involves managing the operational performance of multiple facilities throughout the region to maintain high throughput and quality standards. By optimizing laboratory workflows, Warren Erdmann reduces turnaround times for clinical and anatomic pathology testing. The Chief Operating Officer also coordinates with department heads to implement process improvements that enhance overall productivity and service reliability. Through the management of regional operations, the Chief Operating Officer supports the company's commitment to providing comprehensive diagnostic services, ensuring that every patient and healthcare provider receives consistent, high-quality support regardless of the specific testing requirements or geographic location.

Jessica Bargilione, the Chief Marketing Officer at HNL Lab Medicine, drives the brand strategy and market positioning for the organization. Overseeing the communication of diagnostic capabilities to physician offices, hospitals, and industrial clients, the Chief Marketing Officer ensures that the value proposition of the laboratory remains clear and compelling. This leadership role involves developing outreach programs that highlight the breadth of clinical and anatomic pathology services available across Pennsylvania and New Jersey. By analyzing market data, Jessica Bargilione identifies growth opportunities and tailors service offerings to meet the specific needs of healthcare providers. The Chief Marketing Officer also manages the digital presence and professional relationships that sustain the company's reputation as a leading diagnostic partner. Through strategic brand management, the Chief Marketing Officer expands the reach of the laboratory, ensuring that the organization remains the preferred choice for comprehensive medical testing and diagnostic support in the region.

Jordan Olson, the Chief Medical Officer at HNL Lab Medicine, directs the clinical standards and medical quality assurance for all diagnostic services. Overseeing the pathology teams and laboratory scientists, the Chief Medical Officer ensures that every test result meets the highest benchmarks for accuracy and clinical relevance. This leadership role involves establishing rigorous protocols for clinical and anatomic pathology, ensuring compliance with medical regulations and industry best practices. By mentoring medical staff and reviewing complex diagnostic cases, Jordan Olson maintains the integrity of the laboratory's output. The Chief Medical Officer also collaborates with the executive team to integrate new medical technologies and testing methodologies into the service portfolio. Through the continuous monitoring of clinical performance, the Chief Medical Officer guarantees that the organization provides reliable, evidence-based diagnostic information, ultimately supporting the critical healthcare decisions made by physicians and hospitals throughout the service area.